A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers
Hummingbird Bioscience
Hummingbird Bioscience
H. Lee Moffitt Cancer Center and Research Institute
National Cancer Institute (NCI)
Servier
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Nektar Therapeutics
Akeso
ImmunityBio, Inc.
GlaxoSmithKline
Mahidol University
Washington University School of Medicine
Innate Pharma
Eisai Inc.
State University of New York - Upstate Medical University
University of Chicago
NKGen Biotech, Inc.
UNICANCER
Radboud University Medical Center
Novartis
University of Texas Southwestern Medical Center
NanoCarrier Co., Ltd.
National University Hospital, Singapore
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Azienda Ospedaliero-Universitaria Careggi
Dana-Farber Cancer Institute
University of Pittsburgh
Trans Tasman Radiation Oncology Group
Boneca Corporation
Novartis
Emory University
National Cancer Institute (NCI)
Jiangsu Cancer Institute & Hospital
Bristol-Myers Squibb
University of Tennessee Cancer Institute
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Medical University Innsbruck